AMA submission to the TGA review into the safety and regulatory oversight of unapproved medicinal cannabis products

The AMA has consistently advocated for a robust, evidence-based regulatory framework that ensures patient safety, clinical integrity, and responsible prescribing and dispensing practices. The rapid expansion of medicinal cannabis prescribing — particularly through vertically controlled, direct-to-consumer telehealth models — has exposed significant gaps in the current regulatory framework.